Unicycive Therapeutics Averts Nasdaq Delisting Concerns

Unicycive Therapeutics (UNCY) has released an update.

Unicycive Therapeutics, Inc. faced delisting from the Nasdaq Capital Market after its stock value and bid price fell below Nasdaq’s minimum requirements. However, the company has successfully regained compliance with both the minimum market value and bid price standards, ensuring its continued listing on the exchange. This turnaround may capture the interest of stock market enthusiasts and investors monitoring company performance.

For further insights into UNCY stock, check out TipRanks’ Stock Analysis page.